Nanoformulation of Phytochemicals: A New Frontier in Targeted Drug Delivery and Therapeutic Efficacy

Abstract

Phytochemicals are bioactive substances produced from plants that show promise as treatments for cancer, heart disease, diabetes, and neurological conditions. Poor solubility, fast metabolism, low bioavailability, and restricted tissue targeting, however, impede their clinical translation. Recent developments in nanotechnology have made Nanoformulations an inventive way to get around these restrictions. Advanced pharmacokinetic profiles, enhanced stability, controlled drug release, and site-specific targeting are provided by nanocarrier systems, which include polymeric nanoparticles, liposomes, solid lipid nanoparticles, niosomes, and dendrimers. Curcumin, resveratrol, and quercetin are notable phytochemicals that have been shown to exhibit higher therapeutic efficacy in cancer therapy, particularly hepatocellular carcinoma, with less systemic toxicity when encapsulated in nanoparticles. Neurological problems can now be treated because of the development of nanocarriers that can pass through biological barriers like the blood–brain barrier. Nano-phytochemicals have promise for treating chronic inflammatory diseases, promoting wound healing, and facilitating tissue regeneration, in addition to their oncology applications. Stimuli-responsive ("smart") nanocarriers, green synthesis techniques, and AI-driven formulation design are examples of emerging breakthroughs that improve therapeutic sustainability and precision. Nanoformulation of phytochemicals is a new frontier in targeted drug delivery that holds great potential for next-generation customized treatment, despite obstacles in large-scale manufacture, regulatory approval, and long-term safety monitoring.